Combination of Direct Antiviral Therapy in Hepatitis C Patients, Population of Karachi

2020 ◽  
Author(s):  
Samia Perwaiz Khan
Keyword(s):  
Hepatitis C ◽  
Antiviral Therapy ◽  
Sustained Virological Response Rate ◽  
The Novel ◽  
Qualitative Polymerase Chain Reaction ◽  
Effective Combination ◽  
Function Test ◽  
Initial Regimen ◽  
Polymerase Chain

Background: Pakistan has approximately eight million Hepatitis C Virus infected patients. Initial regimen of interferon-based along with ribavirin showed SVR (Sustained Virological Response Rate) of up to 50%. The new standard ‘DAA therapy’ with improved response rates raised SVR rates to as high as 90%. This study was conducted to determine the outcome of the novel combined DAA regimen in hepatitis C infected patients in Karachi, Pakistan. Methods: Fifty patients with infected with HCV were participants of this study. They were from the gastroenterology ward and OPD Jinnah Medical Hospital (JMCH), Karachi. Initial investigations included blood samples for complete picture (CP) and liver function test (LFT). After performing qualitative Polymerase Chain Reaction (PCR), patients diagnosed with hepatitis C (pangenotypes) were prescribed direct antiviral therapy. Results: Out of total fifty patients diagnosed with HCV infection, forty compensated patients of hepatitis C were prescribed combination of Sofosbuvir and Velpatasvir, of these thirty five patients (100%) had shown to be PCR negative after three months of therapy and negative PCR after 3 months follow-up, five patients were loss to follow. Ten patients decompensated (with ascites, cirrhosis or hepatic encephalopathy) were prescribed Sofosbuvir + Velpatasvir along with ribavirin, seven (100%) had shown to be PCR negative and three were loss to follow. Conclusion: Sofosbuvir and Velpatasvir was most effective combination of direct antiviral regimen in treatment of HCV pan-genotype patients, with least adverse-effects and much better outcome in both compensated and decompensated (with ascites and cirrhosis) hepatitis C infected patients.

scholarly journals Persistent SARS-CoV-2-positive over 4 months in a COVID-19 patient with CHB

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 749-753
Author(s):  
Wenyuan Li ◽  
Beibei Huang ◽  
Qiang Shen ◽  
Shouwei Jiang ◽  
Kun Jin ◽  
...  
Keyword(s):  
The Novel ◽  
Chain Reaction ◽  
Health Crisis ◽  
Public Health Crisis ◽  
Oxygen Inhalation ◽  
New Strategy ◽  
Polymerase Chain ◽  
Novel Coronavirus ◽  
Specific Symptoms

Abstract In recent months, the novel coronavirus disease 2019 (COVID-19) pandemic has become a major public health crisis with takeover more than 1 million lives worldwide. The long-lasting existence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has not yet been reported. Herein, we report a case of SARS-CoV-2 infection with intermittent viral polymerase chain reaction (PCR)-positive for >4 months after clinical rehabilitation. A 35-year-old male was diagnosed with COVID-19 pneumonia with fever but without other specific symptoms. The treatment with lopinavir-ritonavir, oxygen inhalation, and other symptomatic supportive treatment facilitated recovery, and the patient was discharged. However, his viral PCR test was continually positive in oropharyngeal swabs for >4 months after that. At the end of June 2020, he was still under quarantine and observation. The contribution of current antivirus therapy might be limited. The prognosis of COVID-19 patients might be irrelevant to the virus status. Thus, further investigation to evaluate the contagiousness of convalescent patients and the mechanism underlying the persistent existence of SARS-CoV-2 after recovery is essential. A new strategy of disease control, especially extending the follow-up period for recovered COVID-19 patients, is necessary to adapt to the current situation of pandemic.

Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy

2019 ◽  
Vol 51 (6) ◽  
pp. 875-881
Author(s):  
Sabela Lens ◽  
Ferran Torres ◽  
Martin Bonacci ◽  
Concepció Bartres ◽  
Anna Pocurull ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Limited Access

Risk of Transmission and Features of Hepatitis C After Needlestick Injuries

1999 ◽  
Vol 20 (01) ◽  
pp. 63-64 ◽  
Author(s):  
Saeed S. Hamid ◽  
Badar Farooqui ◽  
Qudsia Rizvi ◽  
Tarranum Sultana ◽  
Anwar A. Siddiqui
Keyword(s):  
Hepatitis C ◽  
Healthcare Workers ◽  
Cost Effective ◽  
Asymptomatic Infection ◽  
Needlestick Injury ◽  
Hcv Rna ◽  
Needlestick Injuries ◽  
Cost Effective Method ◽  
Polymerase Chain

Abstract The rate of transmission and management of needlestick injuries from hepatitis C virus (HCV) patients to healthcare workers is still a matter of debate. We used a stringent protocol using monthly transaminase levels and polymerase chain reaction for HCV RNA to monitor 53 healthcare workers prospectively for up to 6 months following needle injuries from HCV-positive patients. Evidence of transmission of HCV was found in only 2 workers (4%) with mild asymptomatic infection, one of which resolved spontaneously. Based on our experience, we now use a less-intensive follow-up protocol. Further investigation is required to determine the most cost-effective method to monitor individuals who suffer a needlestick injury from an HCV-positive patient.

scholarly journals Evidence of hepatitis in patients receiving transfusions of blood components containing antibody to hepatitis C

Blood ◽  
1993 ◽  
Vol 82 (3) ◽  
pp. 1000-1005 ◽  
Author(s):  
SK Aoki ◽  
PV Holland ◽  
LP Fernando ◽  
IK Kuramoto ◽  
S Anderson ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Blood Components ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Immunoblot Assay ◽  
Polymerase Chain ◽  
Hepatitis C Virus Antibody

Abstract When hepatitis C virus antibody (anti-HCV) enzyme immunoassay (EIA1) testing became available in 1990, we tested samples from previously transfused blood units, traced the recipients of reactive units, and evaluated the recipients for HCV infection during the 12 months after transfusion. Ten of 42 recipients of EIA1-reactive blood were anti-HCV reactive on follow-up by EIA1 and 12 were reactive by a second- generation assay (EIA2). Reverse transcriptase-polymerase chain reaction (RT-PCR) detected HCV RNA in 5 seronegative recipients. In all, 17 of 42 recipients (40%) of EIA1-reactive blood had evidence of HCV infection. In comparison, 54 surgery patients, who received either no transfusion or autologous EIA1-nonreactive blood, remained EIA1 nonreactive and RT-PCR negative for 1 year; 1 patient (1.8%) became EIA2 reactive (P < or = .01). Of the recipients of anti-HVC reactive blood transfusions (reactive by both EIA1 and a supplemental 4-antigen strip immunoblot assay [RIBA2]), 14 (93%) of the recipients had evidence of HCV infection compared with only 3 of 27 recipients (11%) of EIA1-reactive, RIBA2-nonreactive blood (P < or = .01). Thus, blood components reactive for anti-HCV EIA1 may have transmitted HCV up to 40% of the time, but blood components found reactive by both EIA1 and RIBA2 may transmit HCV with a frequency of greater than 90%.

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy

2017 ◽  
Vol 29 (7) ◽  
pp. 792-799 ◽  
Author(s):  
Patricia Cordero-Ruiz ◽  
Isabel Carmona-Soria ◽  
Manuel Rodríguez-Téllez ◽  
Angel Caunedo-Alvarez ◽  
Roberto H. Quezada-Pacheco ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Long Term Follow Up

scholarly journals Evidence of hepatitis in patients receiving transfusions of blood components containing antibody to hepatitis C

Blood ◽  
1993 ◽  
Vol 82 (3) ◽  
pp. 1000-1005
Author(s):  
SK Aoki ◽  
PV Holland ◽  
LP Fernando ◽  
IK Kuramoto ◽  
S Anderson ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Blood Components ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Immunoblot Assay ◽  
Polymerase Chain ◽  
Hepatitis C Virus Antibody

When hepatitis C virus antibody (anti-HCV) enzyme immunoassay (EIA1) testing became available in 1990, we tested samples from previously transfused blood units, traced the recipients of reactive units, and evaluated the recipients for HCV infection during the 12 months after transfusion. Ten of 42 recipients of EIA1-reactive blood were anti-HCV reactive on follow-up by EIA1 and 12 were reactive by a second- generation assay (EIA2). Reverse transcriptase-polymerase chain reaction (RT-PCR) detected HCV RNA in 5 seronegative recipients. In all, 17 of 42 recipients (40%) of EIA1-reactive blood had evidence of HCV infection. In comparison, 54 surgery patients, who received either no transfusion or autologous EIA1-nonreactive blood, remained EIA1 nonreactive and RT-PCR negative for 1 year; 1 patient (1.8%) became EIA2 reactive (P < or = .01). Of the recipients of anti-HVC reactive blood transfusions (reactive by both EIA1 and a supplemental 4-antigen strip immunoblot assay [RIBA2]), 14 (93%) of the recipients had evidence of HCV infection compared with only 3 of 27 recipients (11%) of EIA1-reactive, RIBA2-nonreactive blood (P < or = .01). Thus, blood components reactive for anti-HCV EIA1 may have transmitted HCV up to 40% of the time, but blood components found reactive by both EIA1 and RIBA2 may transmit HCV with a frequency of greater than 90%.

scholarly journals Antiviral Effect of Interferon Therapy for Patients with Chronic Hepatitis C

1992 ◽  
Vol 3 (5) ◽  
pp. 305-309 ◽  
Author(s):  
J. Hayashi ◽  
K. Nakashima ◽  
A. Noguchi ◽  
M. Hirata ◽  
K. Akazawa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Effect ◽  
Hcv Rna ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Lymphoblastoid Interferon

Thirty-two patients with chronic hepatitis who were positive for hepatitis C virus (HCV) RNA by polymerase chain reaction and had antibody to HCV (anti-HCV), were enrolled in this study. Twenty of them were also positive for antibody to the GOR epitope (anti-GOR). Sixteen of the enrolled patients were treated with human lymphoblastoid interferon for six months. Treatment was initiated with 3 million units of interferon daily for 2 weeks, followed by 3 million units three times a week for 6 weeks and 1.5 million units three times a week for 16 weeks. The efficacy of therapy was assessed by comparison with the results in 16 untreated patients. Aminotransferase values, titre of anti-HCV and anti-GOR antibodies showed significant decreases throughout the therapy compared with baseline levels and the untreated patients. After a 3 month follow-up, nine treated patients (56.3%) had normal aminotransferase activities and six of them eliminated HCV RNA from their sera (37.5%). Three of these six patients became negative for both anti-HCV and anti-GOR antibodies (18.8%). None of the untreated control patients had normal aminotransferase activities or became negative for HCV markers. The present study suggests that human lymphoblastoid interferon can control the disease activity and eliminate hepatitis C virus from patients with chronic hepatitis C.

A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase

2005 ◽  
Vol 43 (4) ◽  
pp. 599-605 ◽  
Author(s):  
Takeshi Okanoue ◽  
Akiko Makiyama ◽  
Mika Nakayama ◽  
Yoshio Sumida ◽  
Hironori Mitsuyoshi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Antiviral Therapy ◽  
Normal Serum ◽  
Serum Aminotransferase ◽  
Follow Up Study

Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C

2021 ◽  
Vol 15 (9) ◽  
pp. 2823-2825
Author(s):  
Muhammad Abdul Quddus ◽  
Jahangir Zaib ◽  
Rukhsana Munawar ◽  
Rabia Tahir ◽  
Rizwan Saeed Kiani
Keyword(s):  
Hepatitis C ◽  
Antiviral Therapy ◽  
General Medicine ◽  
End Of Treatment ◽  
Detailed Medical History ◽  
Azad Kashmir ◽  
One Year ◽  
Keywords Hepatitis C ◽  
Lost To Follow Up

Aim: To determine the effectiveness of antiviral drugs such as sofosbuvir, daclatasvir and ribavirin in hepatitis C patients and frequency of complications associated to antiviral therapy. Study Design: Prospective study. Place and Duration: This study was conducted at the department of Gastroenterology and General Medicine AK CMH / Sheikh Khalifa bin Zaid Al Nahyan Hospital Rawalakot Azad Kashmir for one year duration from 5th July 2020 to 5th July 2021. Methodology: 150 patients of both genders presented with hepatitis C were included. Patient’s ages were ranging from 25 to 70 years. After taking informed consent from all the patients, detailed medical history including age, sex, residence and education were recorded. Quantitative PCR test was obtained before starting the antiviral therapy, kit method was used. Treatment response was examined after completion of therapy. All the statistical data was analyzed by SPSS 24.0. Results: 88 (58.67%) patients were males while 62 (41.33%) patients were females. Mean age of patients was 48.52±9.38 years. At the end of treatment, 132 (88%) patients were cured and 15 (10%) patients were not cured, 3 (2%) patients had lost to follow-up. Complications associated to therapy were noted as anemia, ascites, hepatic encephalopathy and liver cirrhosis in 40 (26.67%), 20 (13.33%), 7 (4.67%) and 6 (4%) patients respectively. Conclusion: Combination antiviral therapy with Sofosbuvir, daclatasvir and ribavirin shows better results in patients with Hepatitis C with 88% cure rate. Anemia was the most frequent complication found at end of therapy. Keywords: Hepatitis C, Sofosbuvir, Daclatasvir, Ribavirin

Efficacy of antiviral therapy for chronic hepatitis C in children

2021 ◽  
Vol 19 (1) ◽  
pp. 119-123
Author(s):  
O.V. Churbakova ◽  
◽  
D.V. Pechkurov ◽  
T.A. Zhilyakova ◽  
V.G. Akimkin ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Disease Onset ◽  
Virologic Response ◽  
New Drugs ◽  
Hcv Rna

Objective. To analyze the efficacy of antiviral therapy for chronic hepatitis C (HCV) in children. Patients and methods. This study included 58 children aged between 3 and 17 years who had never received antiviral therapy (AVT) before and were treated in the Pediatric Department for Infectious Diseases, N.A.Semashko City Clinical Hospital No 2 (Samara). The inclusion criteria were as follows: confirmed CHC diagnosis and follow-up for at least one year. We analyzed treatment outcomes during an 8-year period, as well as the dynamics of clinical and biochemical parameters in children with HCV depending on their response to AVT. Results. Sustained virologic response (SVR) was achieved in 19 out of 58 children (32.8%) after 24 weeks of therapy and 30 out of 58 children (51.7%) after 48 weeks of therapy. In these children, viral genotypes were distributed as follows: 1b genotype in 19 participants (32.7%), 2a genotype in 4 participants (6.9%), and 3a genotype in 7 participants (12.1%). Twenty-eight patients (71.8%) remained HCV RNA positive, including 1 child with 2a genotype (2.6%), 3 children with 3a genotype (7.7%), and 24 children with 1b genotype (61.5%). Three years after treatment completion, 25 out of 58 patients (43.1%) had SVR. During 8 years of follow-up, 17 out of 30 children (56.7%) maintained SVR. Conclusion. Five out of 58 study participants (8.6%) developed F1–F2 liber fibrosis (METAVIR scale) over 8 years of follow-up. Two out of 58 children with HCV (3,5%) were found to have liver cirrhosis 6.6 ± 1.15 years after the disease onset (minimum – 4 years; maximum – 8 years). New drugs and treatment regimens are needed to increase the SVR rate in children. Key words: children, outcomes, sustained virologic response, chronic hepatitis C

Sign in / Sign up

Export Citation Format

Share Document